汇宇制药：子公司注射用HY0001a完成I期临床试验首例受试者给药

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) announced the successful completion of the first dosing of its self-developed innovative drug HY0001a for the treatment of advanced solid tumors in a Phase I clinical trial [1] Group 1 - The drug HY0001a is classified as a Class 1 innovative biological product and is an antibody-drug conjugate [1] - There are currently no approved products targeting the same site both domestically and internationally [1]